<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931645</url>
  </required_header>
  <id_info>
    <org_study_id>SFGMTC</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00931645</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia</brief_title>
  <acronym>Auto-LLC 2001</acronym>
  <official_title>Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direction Générale de la Santé, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III trial evaluating the role of autologous stem cell transplantation in previously
      untreated patients under 65 years with stage B and C B-cell chronic lymphocytic leukemia.

      Endpoints of the trial :

        -  major : progression free survival at 3 years

        -  secondary : overall survival, tolerance, prognostic factors according to baseline
           clinical stage and biological characteristics (IgHv mutational status, expression of
           ZAP70 and CD38, cytogenetics).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All registered patients will be treated with 6 monthly courses of chemotherapy. First three
      ones will be a CHOP regimen with half dosage of adriamycin, as previously published
      (Effectiveness of &quot;CHOP&quot; regimen in advanced untreated chronic lymphocytic leukemia. French
      Cooperative Group on Chronic Lymphocytic Leukemia. Lancet ; 1986, i : 1346-1349), followed by
      three subsequent courses with IV fludarabine (25 mg/sqm d1-5). Patients in CR (NCI, 1996,
      including CAT scan evaluation) will be then randomized to surveillance without additional
      treatment or autologous stem cell transplantation using peripheral stem cells collected after
      the three first courses of chemotherapy, and/or after the completion of the six courses when
      necessary. For patients not in CR after the six courses, a rescue regimen with the DHAP
      association ( cisplatin, 100 mg/sqm d1, cytarabine 2 g/sqm d2, dexamethasone 40 mg/sqm d1-4)
      will precede an additional stem cell collection if necessary, and patient will be randomized
      between autologous stem cell transplantation and three additional courses of an association
      of fludarabine (25 mg/sqm d1-3) and cyclophosphamide (300 mg/sqm d1-3). Conditioning regimen
      will associate TBI (10 grays, d -3-1) and cyclophosphamide (60 mg/sqm d-5-4).

      Evaluation for response wil be performed before randomisation and two months after completion
      of therapy in each arm.

      Follow-up data will be registered and monitored every three month during the first year, and
      then every six month. Criteria for evaluation of response will use the NCI system (1996).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, response after completion of scheduled treatment, tolerance and adverse events, quality of life, prognostic factors for response and survival.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Complete responders</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>watch and wait policy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2: complete responders patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABMT : TBI, 10 grays d-3-1 &amp; cyclophosphamide 60 mg/sqm d-5-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non CR patients arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rescue chemotherapy and ABMT (see arm 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non CR patients at random : arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rescue DHAP, F+C</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplantation</intervention_name>
    <description>TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)</description>
    <arm_group_label>arm 2: complete responders patients</arm_group_label>
    <other_name>ABMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DHAP rescue and Autologous stem cell transplantation</intervention_name>
    <description>DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)</description>
    <arm_group_label>Non CR patients arm 3</arm_group_label>
    <other_name>cisplatin</other_name>
    <other_name>dexamethasone</other_name>
    <other_name>cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DHAP rescue and F+C</intervention_name>
    <description>DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) &amp; cyclophosphamide (300 mg/sqm)</description>
    <arm_group_label>Non CR patients at random : arm 4</arm_group_label>
    <other_name>Fludarabine</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with stage B &amp; C CLL, 18- 65 years.

          -  previously untreated

          -  given written informed consent

        Exclusion Criteria:

          -  Childbearing women

          -  OMS Performance status &gt; 2

          -  Binet stage A

          -  Autoimmune hemolytic anemia

          -  Active or previous (&lt; 5 years) malignant disease, except cutaneous cell carcinoma.

          -  Previous CLL treatment

          -  HIV seropositivity

          -  Abnormal renal or liver function tests (creatinine &gt; 1,5N, transaminases &gt; 2N,
             bilirubin &gt; 1,5N)

          -  Cardiac failure (ejection fraction &lt; 50%)

          -  Lung disease or perturbed ventilation tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sutton Laurent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Victor Dupouy Argenteuil, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leporrier Michel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CaenUH, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DBIM Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>July 1, 2009</last_update_submitted>
  <last_update_submitted_qc>July 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Laurent Sutton MD</name_title>
    <organization>SFGM-TC</organization>
  </responsible_party>
  <keyword>Chronic lymphocytic leukemia,</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

